Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01STB
|
|||
| Former ID |
DAP000581
|
|||
| Drug Name |
Ramipril
|
|||
| Synonyms |
Acovil; Altace; Carasel; Cardace; Delix; Hypren; Hytren; Lostapres; Naprix; Pramace; Quark; Ramace; Ramiprilum; Triatec; Tritace; Vesdil; Zabien; Almirall Brand of Ramipril; Astra Brand of Ramipril; AstraZeneca Brand of Ramipril; Aventis Brand of Ramipril; Aventis Pharma Brand of Ramipril; Hoechst Brand of Ramipril; Monarch Brand of Ramipril; Promed Brand of Ramipril; Ramiprilum [Latin]; HOE 498; HOE498; Altace (TN); Hoe-498; Pramace (discontinued); Tritace (TN); Ramipril (USP/INN); Ramipril [USAN:INN:BAN]; Ramipro, Tritace, Altace, Prilace, Ramipril; N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid; [2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen; [2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2 S ,3 aS,6 aS)-1[(S)-N-[(S)-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester; (2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure; (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid; (2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name); (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid; (2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic; (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p; (2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50; ICD-9: 428] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H32N2O5
|
|||
| Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
|
|||
| InChI |
1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1
|
|||
| InChIKey |
HDACQVRGBOVJII-JBDAPHQKSA-N
|
|||
| CAS Number |
CAS 87333-19-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7847487, 7980483, 11364914, 11367476, 11370038, 11372946, 11374996, 11378208, 11491609, 11493083, 11495772, 11528643, 11533329, 12012944, 14904601, 14929182, 17184929, 24724586, 26612834, 26719894, 39384402, 46386770, 46506390, 47721705, 48244488, 48416510, 49664947, 49681721, 50122729, 53787042, 57362088, 76755897, 81093204, 85279379, 92308080, 92308314, 92309227, 92712074, 93166961, 103339774, 103984211, 104170125, 104179208, 104253384, 114149719, 117664421, 121362522, 124658840, 124757502, 124799903
|
|||
| ChEBI ID |
CHEBI:8774
|
|||
| ADReCS Drug ID | BADD_D01909 | |||
| SuperDrug ATC ID |
C09AA05
|
|||
| SuperDrug CAS ID |
cas=087333195
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides cellulosilyticus DSM 14838
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides cellulosilyticus DSM 14838 (log2FC = -0.41; p = 0.043). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.692; p = 0.017). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.441; p = 0.045). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.76; p = 0.029). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.65; p = 0.034). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.506; p = 0.015). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Eubacterium biforme DSM 3989
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ramipril can be metabolized by Eubacterium biforme DSM 3989 (log2FC = -0.377; p = 0.007). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Renin-angiotensin system | |||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6339). | |||
| REF 2 | Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.